• Metabolic and pharmacokinetic properties (e.g., metabolic 

 degradation products, depuration kinetics) 



• Toxicological effects (e.g., target organs, cytotoxicity, car- 

 cinogenicity, mutagenicity) according to specific uptake route 

 of concern (i.e., ingestion). 



A toxicity profile may consist of an IRIS chemical file. An example file 

 taken from IRIS is provided in Appendix B. 



The key elements of a hazard assessment should be summarized in a 

 concise tabular format. The examples shown in Table 3 and in the first 

 two sections of the IRIS file (Chronic Systemic Toxicity; Risk Estimates 

 for Carcinogens) in Appendix B illustrate the kinds of information used 

 to evaluate toxicological hazards. Neither toxicity profile in Table 3 is 

 intended to be comprehensive. 



Acute Toxicity 

 Human LD50 (mg/kg body wt) 29« 



Mammal LD50 (mg/kg body wt ) 1 .0 - 40.9 



Chronic Toxicological Effects 

 Humans 



Mammals 



Critical endpoint for risk as- 

 sessment 



Motor and sensory im- 

 pairment leading to 

 paralysis, loss of vision 

 and hearing, and death. 

 Kidney dysfunction. 



Reproductive impair- 

 ment and teratogenic ef- 

 fects. 



1,010-16,000 



Skin lesions, liver 

 dysfunctions, and 

 sensory neuropathy. 

 Possible reproduc- 

 tive and develop- 

 mental impairment. 



Ilcpaloxicity, 

 fetotoxicity, skin 

 lesions, and hepato- 

 cellular carcinoma. 

 Reproductive and 

 developmental im- 

 pairment. 



Central nervous system Hepatocellular car- 

 effects (e.g., ataxia and cinoma . 

 parathesia) . 



20 



